Disease · MONDO_0018013
complement 3 glomerulopathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. complement 3 glomerulopathy. Diseases, record MONDO_0018013. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018013
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
C3 glomerulopathy, C3G, non-Ig-mediated MPGN, non-Ig-mediated membranoproliferative glomerulonephritis, non-immunoglobulin-mediated MPGN, non-immunoglobulin-mediated membranoproliferative glomerulonephritis
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PEGCETACOPLAN | CHEMBL4298211 | Protein | Approval | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| IPTACOPAN | CHEMBL4594448 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DANICOPAN | CHEMBL4250860 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALISKIREN | CHEMBL1639 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DARATUMUMAB | CHEMBL1743007 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TELITACICEPT | CHEMBL5095293 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VENSOBAFUSP ALFA | CHEMBL5314785 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ZALTENIBART | CHEMBL6068191 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| RUXOPRUBART | CHEMBL6068459 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| C3 | Complement C3 | 1 | Complement C3 inhibitor | Approval | https://conductscience.org/library/genes/718 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| CFB | Complement factor B | 1 | Complement factor B inhibitor | Phase 3 | https://conductscience.org/library/genes/629 | Drugs and targets |
| CFD | Complement factor D | 1 | Complement factor D inhibitor | Phase 2 | https://conductscience.org/library/genes/1675 | Drugs and targets |
| REN | Renin | 1 | Renin inhibitor | Phase 2 | https://conductscience.org/library/genes/5972 | Drugs and targets |
Trials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05067127 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | Phase 3 | 124 | 2025-08-06 | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT03832114 | Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted | Phase 2 | 27 | 2022-07-08 | Glomerulonephritis | IPTACOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT03459443 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 | Phase 2 | 22 | 2022-08-11 | C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease | DANICOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT03453619 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | Phase 2 | 21 | 2025-02-13 | IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | Phase 2 | 13 | 2021-11-04 | C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease | DANICOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT04572854 | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | Phase 2 | 13 | 2025-02-07 | C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT03095118 | Daratumumab in Treatment of PGNMID and C3 GN | Phase 2 | 12 | 2021-07-16 | Membranoproliferative Glomerulonephritis | DARATUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | Phase 2 | 6 | 2021-07-13 | C3 Glomerulonephritis, Dense Deposit Disease, C3 Glomerulopathy, Immune Complex Mediated Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis Types I, II, and III | DANICOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT03955445 | Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | Phase 3 | 225 | C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | IPTACOPAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05809531 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | Phase 3 | 100 | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Danicopan (Double-blind Treatment Period) vs Placebo (Double-blind Treatment Period): Participants With Significant Improvement In eGFR Relative To Baseline At Week 28 | 0 of 6 | 0 of 5 | 11 | NCT03369236 | Trial comparisons |
Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) vs Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period): Participants With Significant Improvement In eGFR Relative To Baseline At Week 52 | 0 of 5 | 0 of 5 | 10 | NCT03369236 | Trial comparisons |
| Danicopan (Double-blind Treatment Period) vs Placebo (Double-blind Treatment Period): Participants With Reduction In Proteinuria At Week 28 | 0 of 4 | 1 of 5 | 9 | NCT03369236 | Trial comparisons |
| Group 1: Danicopan 100 mg TID (Sentinel) vs Group 2: Danicopan up to 200 mg TID: deaths from any cause | 0 of 2 | 0 of 4 | 6 | NCT03124368 | Trial comparisons |
| Group 1: Danicopan 100 mg TID (Sentinel) vs Group 2: Danicopan up to 200 mg TID: serious adverse events | 0 of 2 | 1 of 4 | 6 | NCT03124368 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018013
GET https://conductscience.org/api/diseases/v1/MONDO_0018013/drugs